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Purpose: We evaluated the efficacy and safety of febuxostat, a non-purine xanthine oxidase inhibitor, used for
prevention of hyperuricemia associated with tumor lysis syndrome (TLS).
Methods: Records of adult patients with newly diagnosed or relapsed hematologic malignancies who received
febuxostat within 7 days before initiation of chemotherapy were retrieved retrospectively at a single institute.
The changes in serum uric acid levels from before and 7 days after initiation of febuxostat were evaluated and compared
with the historical control group of patients who received allopurinol. We also evaluated non-hematological adverse
events during the study period.
Results: A total of 78 patients’ records were analyzed, 38 in the febuxostat group and 39 in the allopurinol group. There
were no significant differences in the incidence of treatment failure, defined as development of clinical TLS or receiving
rasburicase, between the febuxostat and allopurinol group (5.2% vs 5.1%, P>0.99). The mean serum uric acid levels
were significantly decreased, compared to the baseline (5.6 ± 2.1 mg/dL), at 7 days after initiation of febuxostat
(3.1 ± 1.5 mg/dL, last observation carried forward, P<0.001). There were no statistically significant differences in the
percent change in the serum uric acid levels between the 40 mg/day febuxostat and the 300 mg/day allopurinol
groups (P = 0.57). Grade 3–4 liver dysfunctions were observed in both the febuxostat and allopurinol groups,
without significant differences in incidence between the two groups (2.6% vs 5.1%, P>0.99). Neither gout flare
nor skin rash occurred in any patients.
Conclusions: Febuxostat is feasible for prevention of hyperuricemia associated with TLS.
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Tumor lysis syndrome (TLS) is a life-threatening meta-
bolic complication caused by tumor cell lysis, usually
after initial chemotherapy for malignant disease. TLS is
characterized by hyperkalemia, hyperphosphatemia, hypo-
calcemia, and hyperuricemia, and as a consequence, acute
kidney injury, cardiac arrhythmia, and seizure. Among
these, hyperuricemia leads to deposition of uric acid and
calcium phosphate crystals in the renal tubules, resulting in
acute kidney injury (Davidson et al. 2004). The risk of TLS
is estimated by tumor- and patient-related factors in each
patient. Hypouricemic agents, such as rasburicase and* Correspondence: schiba-t@md.tsukuba.ac.jp
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in any medium, provided the original work is pallopurinol, have been used for prevention of TLS by redu-
cing the level of serum uric acid. Evidence-based guidelines
published by international expert panels recommend ras-
buricase for high- or intermediate-risk, and allopurinol for
intermediate- or low-risk of TLS (Coiffier et al. 2008; Cairo
et al. 2010; Pession et al. 2011). Allopurinol is a purine ana-
log that competitively inhibits xanthine oxidase, blocks the
metabolism of hypoxanthine and xanthine to uric acid, and
reduces the incidence of obstructive uropathy in patients
with a TLS risk (Krakoff and Meyer 1965). However, there
are several limitations to its use due to allopurinol hyper-
sensitivity, characterized by fever, skin rash, and hepatic
dysfunction, which can be lethal. We need to reduce the
dose of allopurinol in patients with renal insufficiency, be-
cause allopurinol hypersensitivity is more frequent among
them (Ramasamy et al. 2013). However, dose adjustment ofOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Table 1 Patient characteristics
Febuxostat Allopurinol P value
No. of patients 38 39
Agea 62.5 (26–83) 64 (25–79) 0.46
Body weightb, kg 61 ± 12 53 ± 12 0.0051
Diseasec, n 0.24
Acute myeloid leukemia 10 10
Acute lymphoblastic leukemia 0 4
Non-Hodgkin lymphoma
aggressive B-cell 6 10
indolent B-cell 11 9
T-cell 4 3
Others 7 3
Serum creatinineb, mg/dL 0.90 ± 0.39 0.76 ± 0.30 0.071
Renal dysfunctionc, n (%) 0.0073
Yes 14 (37%) 4 (10%)
TLS riskc, n 0.30
Low 18 12
Intermediate 18 24
High 2 3
Serum LDHb, IU/L 395 ± 360 468 ± 542 0.49
Serum uric acidb, mg/dL
Overall 5.8 ± 2.3 5.4 ± 1.6 0.41
Patients not receiving rasburicase 5.6 ± 2.1 5.4 ± 1.6 0.73
aMedian (range). P values were analyzed by Mann–Whitney U test.
bMean ± SD. P values were analyzed by t-test.
cFischer’s exact test were used for categorical variables.
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sulted in an unsatisfactory hypouremic effect from the allo-
purinol (Dalbeth et al. 2006). Febuxostat, a non-purine
selective xanthine oxidase inhibitor, is indicated for use in
the treatment of hyperuricemia. Febuxostat has an advan-
tage over allopurinol in that hypersensitivity is less frequent
so that no dose adjustment is necessary for patients with
mild to moderate renal impairment (Mayer et al. 2005). It
is supposed that febuxostat is effective for prevention of hy-
peruricemia associated with TLS and also feasible in this
setting, but there has been no published report supporting
such a hypothesis. In this study, we report the retrospective
analysis of febuxostat for prevention of hyperuricemia asso-
ciated with TLS.
Methods
Patients
Records of consecutive adult patients with newly diag-
nosed or relapsed hematologic malignancies who re-
ceived febuxostat within 7 days before the initiation of
chemotherapy between April 2012 and March 2013 at
the University of Tsukuba Hospital were retrieved retro-
spectively. Patients who received allopurinol between
November 2011 and December 2012 were used as the
historical control. Patients who had already received
febuxostat or allopurinol for hyperuricemia or gout were
excluded.
TLS risk
The definition of TLS risk was based on the previously
reported expert panels (Coiffier et al. 2008; Cairo et al.
2010). Renal dysfunction was defined by serum crea-
tinine levels higher than ULN in our hospital. Patients
with a low- or intermediate-risk disease were regarded
as having an intermediate or high risk for TLS, respec-
tively, when renal dysfunction and/or renal involvement
were present. Patients with an intermediate-risk disease
and elevated serum uric acid, phosphate, or potassium
levels were also categorized as having a high risk for
TLS. The definition of laboratory and clinical TLS was
adopted from a previous report (Coiffier et al. 2008).
Treatment
Patients in the historical allopurinol group were treated
with 300 mg/day of allopurinol for TLS prophylaxis.
Some patients received lower doses of allopurinol,
mainly due to renal insufficiency. For the febuxostat
group, we prescribed lower doses (10–20 mg/day) of
febuxostat in the early period after starting to use
febuxostat in our institute, because the Pharmaceuticals
and Medical Devices Agency in Japan and the Japanese
guideline for prophylaxis of TLS (Japanese Society of
Medical Oncology 2013) recommended lower doses of
febuxostat. With time and experience, the initial doseconstraint was gradually removed, and we changed our
institutional manual to using 40 mg/day of febuxostat at
initial dose.
Efficacy evaluation
Treatment failure was defined as development of clinical
TLS or receiving rasburicase. Serum uric acid levels
were compared before and 7 days after the initiation of
febuxostat (last observation carried forward). Percent
changes in the serum uric acid levels were compared be-
tween the 10, 20, and 40 mg/day febuxostat groups and
the 300 mg/day allopurinol group. Patients who received
rasburicase were excluded from these evaluations.
Safety evaluation
Non-hematological adverse events were evaluated by the
worst grades during the observation period, according to
the Common Terminology Criteria for Adverse Events
version 4.0 (http://ctep.cancer.gov/protocolDevelopment/
electronic_applications/ctc.htm#ctc_40). We did not evalu-
ate hematological adverse events, because those events
were strongly influenced by the concomitantly adminis-
trated anticancer drugs.
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The serum uric acid levels are shown as mean ± SD. Com-
parisons of categorical data were analyzed by Fisher’s exact
test. Patient age was compared by Mann–Whitney U test.
Patient actual body weight, serum LDH, and uric acid level
were analyzed by 2-sample t-test. Overall change in the uric
acid levels before and after the initiation of hypouricemic
drugs was evaluated by paired t test. Percent changes in
serum uric acid level were compared by two-sample t test.
In a previous report, the reduction of the serum uric acid
level 16 weeks after the administration of 300 mg/day of
allopurinol was 36.55 ± 18.59% (Naoyuki et al. 2011).
Therefore, 3.66% was set as the non-inferiority margin
when we compared 40 mg/day of febuxostat with 300 mg/
day of allopurinol for the present study. P values were two-
sided and P<0.05 was considered to be significant.
All statistical analyses were performed with the soft-
ware “EZR” (Saitama Medical Center, Jichi Medical
University, version 1.20), which is a graphical user
interface for R (The R Foundation for Statistical Com-
puting, version 3.0.2). More precisely, it is a modified
version of R commander (version 2.0-1) designed to
add statistical functions frequently used in biostatistics
(Kanda 2013).0
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Figure 1 Overall serum uric acid profiles. Error bars represent standardResults
Patients
A total of 78 consecutive patients, 39 receiving febuxo-
stat and 39 receiving allopurinol, were included in this
study, with one patient in the febuxostat group excluded
from the analysis due to lack of pre-treatment evaluation
of serum uric acid level. The number of patients who re-
ceived 10, 20, and 40 mg/day of febuxostat were 9, 7,
and 22, respectively. The number of patients who re-
ceived 50, 100, 200, and 300 mg/day of allopurinol were
2, 4, 4, and 29, respectively. Table 1 shows the patient
characteristics. There was a significant difference in the
proportion of patients with renal dysfunction between
the febuxostat and the allopurinol group (37% vs 10%,
P = 0.0073). The number of patients with renal dysfunction
who received 10, 20, and 40 mg/day of febuxostat were 5,
3, and 6, respectively.
Efficacy
Two patients in the 20 mg/day febuxostat group devel-
oped clinical TLS and received rasburicase. One patient
in the 300 mg/day allopurinol group developed clinical
TLS, but rasburicase was not administered. One patient
in the 300 mg/day allopurinol group received rasburicasePost
Febuxostat
Allopurinol
3.1 1.5
3.0 1.5
 pre vs post, paired t-test
deviation.
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significant difference in the incidence of treatment fail-
ure between the febuxostat and the allopurinol group
(5.2% vs 5.1%, P>0.99).
The mean serum uric acid levels were significantly de-
creased in both the febuxostat (from 5.6 ± 2.1 to 3.1 ±
1.5, P<0.001) and allopurinol (from 5.4 ± 1.6 to 3.0 ±
1.5, P<0.001) groups (Figure 1).
In analysis of individual patients, the mean percent
changes for the 10, 20, and 40 mg/day febuxostat and
300 mg/day allopurinol group were −22% (n = 9; 95%
CI, −43% to −0.48%), −28% (n = 5; 95% CI, −63% to
7.8%), −54% (n = 22; 95% CI, −62% to −46%), and −51%
(n = 28; 95% CI, −58% to −44%), respectively (Figure 2).
There were significant differences in percent changes
of the serum uric acid levels between the 10 and the
40 mg/day febuxostat groups (P<0.001), and between
the 20 and the 40 mg/day febuxostat groups (P =
0.013), whereas there were no significant differences
between the 40 mg/day febuxostat and the 300 mg/day
allopurinol groups (P = 0.57). The difference in the per-
cent changes of serum uric acid between 300 mg/day
allopurinol and 40 mg/day febuxostat was −2.8% (95%
CI, −12.7% to 7.1%; note that the positive value is for
the inferiority of febuxostat against allopurinol). In this-80
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Figure 2 Percent change in serum uric acid. Error bars represent standastudy, the non-inferiority margin was set at 3.66%;
thus, 40 mg/day febuxostat is not significantly inferior
to 300 mg/day allopurinol.
Safety
One patient receiving 10 mg/day of febuxostat deve-
loped grade 3 γ-GT elevation. One patient receiving
300 mg/day of allopurinol developed grade 3 AST eleva-
tion, and 1 patient receiving 200 mg/day of allopurinol
developed grade 3 γ-GT elevation. Neither gout flare
nor skin rash occurred in any patients. There were no
significant differences in the incidence of Grade 3–4
liver dysfunction between the febuxostat and the allo-
purinol group (2.6% vs 5.1%, P>0.99).
Discussion
In the present study, we have shown that febuxostat re-
duced serum uric acid levels in clinical use for preven-
tion of hyperuricemia associated with TLS. There was
no statistical difference in percent change in the serum
uric acid level between 40 mg/day febuxostat and
300 mg/day allopurinol. In this study, febuxostat was
well tolerated with the initial dose of 10–40 mg/day in
all the patients analyzed, including those who suffered
from preexisting renal dysfunction.g 40 mg 300 mg
stat Allopurinol
P = 0.57
= 0.013
01
rd deviation.
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and allopurinol at the dose of 40 mg/day and 300 mg/
day, respectively, showed an equally potent effect in re-
ducing the serum uric acid levels for patients with non-
tumor-associated hyperuricemia, when compared before
and 16 weeks after the initiation of administration
(Naoyuki et al. 2011). Our results could not strictly re-
produce the equality of the two drugs demonstrated in
the previous study. It may be because of the difference
in the target diseases, much earlier evaluation than the
previous study, and the small sample size. In our study,
febuxostat was shown to have a hypouricemic effect in a
manner dependent on the initial dose, and to be well tol-
erated at each initial dose. Lower doses of febuxostat, how-
ever, might be insufficient for the prophylaxis of TLS
because 2 out of 7 patients who received 20 mg/day of
febuxostat developed TLS. Thus, 40 mg/day of febuxostat
may be appropriate for sufficient control of TLS.
There are several limitations to this study. The back-
grounds, such as disease and supportive therapy except
for hypouricemic agents, were varied. In addition some
patients who were defined as having a low TLS risk
might not have needed febuxostat or allopurinol. Al-
though the superiority or even non-inferiority of febuxo-
stat at 40 mg/day to allopurinol at 300 mg/day was not
proven with the current sample size, our results suggest
that at least the equality or non-inferiority of febuxostat
might be demonstrated if the sample size is increased. If
so, we could conclude that febuxostat is more useful
than allopurinol, given the difference in the necessity for
dose reduction. Thus, prospective randomized con-
trolled trials in a larger cohort are warranted. Moreover,
if we had evaluated serum and urine levels of purine
precursors, it might have provided a better insight, be-
cause both febuxostat and allopurinol increase xanthine
levels, and xanthinuria may lead to kidney injury (Hande
et al. 1981).Conclusions
In conclusion, our data suggest that febuxostat is feasible
for prevention of hyperuricemia associated with TLS.
More comparison with allopurinol is required with lar-
ger cohorts, possibly in a prospective setting.Abbreviations
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